Biometrics Co-op

Moderna adds Chief Operating Officer role as company expands into oncology. Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna CAMBRIDGE, Mass., September 30, 2026 (Newswire.com) - Moderna, Inc. (NASDAQ:MRNA) today announced the addition of a Chief Operating Officer role to support the increasing scale and diversification of the Company. The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader oncology portfolio. The Company has also expanded the infectious disease franchise, which now includes five approved vaccines following the recent U.S. FDA approval of Moderna's seasonal flu vaccine and the European Commission marketing authorization of the Company's seasonal flu plus COVID combination vaccine. Juan Andres will return to Moderna as Chief Operating Officer, effective October 5, 2026. Mr. Andres will report to Chief Executive Officer Stéphane Bancel and serve on the Company's Executive Committee. As Chief Operating Officer, Mr. Andres will work across the Company to help drive focus, prioritization and execution while leading the manufacturing organization. Moderna also announced that Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, has decided to retire from the Company. "I am very pleased to welcome Juan back to Moderna as our Chief Operating Officer," said Stéphane Bancel, Chief Executive Officer of Moderna. "As we enter the next chapter of Moderna, Juan's experience leading complex global operations will be invaluable. He knows Moderna deeply and was an extraordinary partner to me as we built and scaled the Company. I look forward to working with him again as we execute on our strategy." Mr. Andres previously spent nearly six years at Moderna, joining the Company in 2017 and serving as Chief Technical Operations and Quality Officer from 2018 through 2022. He later served as President, Strategic Partnerships and Enterprise Expansion before retiring from Moderna in 2023. During his tenure, he led the build-out and unprecedented scale-up of Moderna's manufacturing capabilities, including the rapid expansion of the Company's global manufacturing network to support the production and supply of Moderna's COVID-19 vaccine. "I am excited to return to Moderna at such an important moment for the Company," said Mr. Andres. "Moderna has always been a special place to me, and the opportunity ahead is tremendous. I look forward to working with Stéphane and colleagues across the Company to execute on our priorities and deliver more mRNA medicines to patients around the world." "I am also deeply grateful to Jerh for his leadership, partnership and commitment to Moderna over the past four years," said Mr. Bancel. "He has made significant contributions to our Company and built a very strong team that will carry forward the important work of manufacturing and technical operations. I wish Jerh and his family all the best in his retirement." "It has been a privilege to be part of Moderna and to lead our Technical Operations and Quality organization," said Dr. Collins. "I am incredibly proud of what our teams have accomplished together for patients, and grateful to the many colleagues I have had the opportunity to work alongside. As I look ahead to retirement, I have great confidence in the team and in Moderna's future." Dr. Collins joined Moderna in October 2022 and became Chief Technical Operations and Quality Officer in January 2023. During his tenure, he helped transition Moderna's manufacturing footprint for an endemic vaccine market, advanced the Company's manufacturing capabilities in the UK, Canada and Australia, and established the manufacturing model to support intismeran autogene. Prior to Moderna, he spent nearly 30 years at Novartis in roles of increasing responsibility across pharmaceutical production and manufacturing. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. About Moderna Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more. With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the Company's appointment of Mr. Andres as Chief Operating Officer, the potential launch and scale-up of intismeran autogene, the advancement of Moderna's business and oncology portfolio, and the Company's strategy, priorities and plans to deliver mRNA medicines. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof. Moderna Contacts Media: Chris Ridley Vice President, Global Head of Communications +1 617-800-3651 [email protected] Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 [email protected]

Moderna has appointed Juan Andres as Chief Operating Officer, effective 5 October 2026, as the company expands its operations into oncology. Andres previously worked at Moderna from 2017 to 2023, leading the build-out of its manufacturing capabilities during the COVID-19 vaccine scale-up. The new role supports Moderna's preparation for the potential launch of intismeran autogene following positive Phase 3 results and the advancement of its broader oncology portfolio. The company's infectious disease franchise now includes five approved vaccines, following recent US FDA approval of its seasonal flu vaccine and European Commission authorisation of its flu-COVID combination vaccine. Jerh Collins, Chief Technical Operations and Quality Officer, will retire after four years with the company. Andres will oversee manufacturing operations and work across the organisation to drive execution of Moderna's strategy.

Pfizer, Moderna face Bayer patent lawsuit. A federal judge in Delaware has rejected efforts by Pfizer, BioNTech and Moderna to dismiss patent infringement lawsuits brought by Bayer's Monsanto unit over technology allegedly used in their COVID-19 vaccines. The ruling allows the cases to move forward, keeping a dispute over the ownership and use of mRNA-related technology active in federal court. The lawsuits were filed by Bayer CropScience LLC, Monsanto Company and Monsanto Technology LLC. Bayer alleges that Pfizer, BioNTech and Moderna used patented technology originally developed by Monsanto to modify and stabilize messenger RNA, or mRNA. According to Bayer, the technology was developed decades ago for agricultural applications but was later incorporated into processes used in COVID-19 vaccines. The patent at issue is U.S. Patent No. 7,741,118, which concerns methods for modifying gene sequences. Bayer alleges that the technology covered by the patent was used to improve the stability and performance of genetic material incorporated into the vaccines. The companies challenged the lawsuits at an early stage, arguing that Bayer's patent claims should not be allowed to proceed. They disputed Bayer's interpretation of how the patented technology works and argued that their vaccine manufacturing processes were different from the technology covered by the patent. Moderna also argued that the patent was directed toward an unpatentable natural phenomenon. U.S. Circuit Judge William Bryson, sitting by designation in the Delaware federal court, rejected the requests to dismiss the cases. The judge concluded that the vaccine manufacturers had not demonstrated at this stage that the patent was invalid or that their vaccines did not infringe it. The decision therefore does not establish that Pfizer, BioNTech or Moderna infringed the patent. Instead, it means Bayer's allegations have survived the companies' attempts to end the litigation before further proceedings. The lawsuits against Pfizer and Moderna were filed separately in the U.S. District Court for the District of Delaware. BioNTech is also named in the litigation involving Pfizer. The cases will now continue through the federal litigation process, where the parties can present additional evidence and arguments concerning the patent's validity, scope and alleged use. Bayer's lawsuits are part of a broader series of intellectual-property disputes involving mRNA technology. The rapid development and commercial success of COVID-19 vaccines generated significant patent litigation as pharmaceutical companies, universities and other organizations asserted competing rights over technologies used in vaccine development and manufacturing. Bayer previously filed related litigation against Johnson & Johnson concerning the same patent, with that case proceeding separately in New Jersey. The latest Delaware ruling does not determine damages or establish that the defendants are liable for infringement. Those issues would have to be resolved later if Bayer ultimately succeeds on its claims. For now, the immediate legal development is that Pfizer, BioNTech and Moderna were unsuccessful in their efforts to have the Delaware lawsuits dismissed at the preliminary stage. The decision could therefore lead to additional litigation over the scope and validity of Bayer's patent and whether the technology used in the companies' vaccines falls within its claims. The outcome could also have broader implications for disputes over intellectual-property rights surrounding mRNA technology, although the court's ruling itself is limited to the issues presented at this stage of the cases. Key legal outcome. * A federal judge in Delaware denied requests by Pfizer, BioNTech and Moderna to dismiss Bayer's patent lawsuits. * The lawsuits concern alleged infringement involving mRNA technology used in COVID-19 vaccines. * The court found the companies had not established at this early stage that Bayer's patent was invalid or that their vaccines did not infringe it. * The ruling does not establish that the companies infringed the patent; it allows Bayer's claims to continue through litigation. * The separate cases against Pfizer/BioNTech and Moderna remain pending in the U.S. District Court for the District of Delaware. Why it matters. * The ruling keeps a significant intellectual-property dispute involving COVID-19 vaccine technology alive. * Bayer will have an opportunity to continue pursuing its patent infringement allegations in federal court. * Pfizer, BioNTech and Moderna will have to defend against the claims rather than having the cases dismissed at this stage. * The litigation could require the court to examine how the companies' mRNA manufacturing processes relate to Bayer's patented technology. * The case adds to the broader body of litigation surrounding ownership and patent rights in mRNA technology. Janice Thompson Janice Thompson enjoys writing about business, constitutional legal matters and the rule of law.